The new golden era for radioimmunotherapy: not just for lymphomas anymore.

نویسندگان

  • Michael B Tomblyn
  • Michaek J Katin
  • Paul E Wallner
چکیده

BACKGROUND Radioimmunotherapy (RIT) has been approved for the treatment of B-cell non-Hodgkin lymphomas in the United States for more than a decade. However, the history of the development of RIT agents for advanced-stage solid malignancies dates back much further, and recent advances have renewed interest in this approach for solid tumors. METHODS This paper reviews available evidence for the preclinical and clinical development of RIT agents for solid tumors. RESULTS Several RIT agents have been studied for the treatment of a variety of solid malignancies, particularly colorectal, breast, prostate, ovarian, pancreatic, hepatocellular, and primary brain tumors. Multiple novel RIT agents are in active clinical investigation, either as single agents or combined with radiosensitizing chemotherapy or with external beam radiotherapy. Improvements in antibody (and antibody fragment) design and the availability of novel radionuclides have improved the therapeutic window for these agents. CONCLUSIONS RIT for solid malignancies shows promise, typically with fewer adverse events than traditional cytotoxic systemic therapy. The greatest efficacy will likely be in the adjuvant setting of minimal residual disease. Newer radionuclides, particularly alpha-emitters, offer increased antitumor potency with less toxicity. Physicians and patients should be encouraged to participate in clinical trials of these promising agents.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

آزمون دو نظریه پیمون و مستطیل طلایی ایرانی در خانه‌های دوره قاجار شیراز

The golden ratio has been claimed to have held a special fascination for at least 2,400 years. Some of the greatest mathematical minds of all ages, from Pythagoras and Euclidian ancient Greece, through the medieval Italian mathematician Leonardo of Pisa and the Renaissance astronomer Johannes Kepler, to present-day scientific figures such as Oxford physicist Roger Penrose, have spent endless ho...

متن کامل

Pretargeted radioimmunotherapy for B-cell lymphomas.

Relapsed or treatment refractory B-cell lymphomas are currently incurable with conventional chemotherapy and radiation treatments. High-dose chemoradiotherapy and stem cell transplantation can cure some patients with relapsed or refractory lymphoma, but the majority of such patients die of progressive disease. We have investigated the potential utility of pretargeted radioimmunotherapy using mo...

متن کامل

Radioimmunotherapy: a brief overview

With the advent of biotechnological advances and knowledge of molecular and cellular biology, radioimmunotherapy (RIT) has become a highly promising oncologic therapeutic modality with established clinically efficacy, particularly in non-Hodgkin's lymphomas. This paper provides a short survey of the basic science of RIT and the various monoclonal antibodies and radionuclides used. A brief revie...

متن کامل

Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.

Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have meas...

متن کامل

Cutaneous lymphomas and pseudolymphomas: A ten-year study at Emam Reza and Omid hospitals in Mashhad, using immunohistochemical and new classification methods

Background: Cutaneous lymphomas are monoclonal neoplastic proliferations of immune cells most frequently T or B cells that infiltrates skin. Development of new diagnostic methods, particularly those for immunophenotyping, have substantially changed classification of these neoplasms. These reasons prompted us to perform this study. Objective: To re-classify cutaneous lymphomas and pseudoly...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Cancer control : journal of the Moffitt Cancer Center

دوره 20 1  شماره 

صفحات  -

تاریخ انتشار 2013